|
[1]
|
Lang, J., Narendrula, A., El-Zawahry, A., et al. (2022) Global Trends in Incidence and Burden of Urolithiasis from 1990 to 2019: An Analysis of Global Burden of Disease Study Data. European Urology Open Science, 35, 37-46. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Chewcharat, A. and Curhan, G. (2021) Trends in the Prev-alence of Kidney Stones in the United States from 2007 to 2016. Urolithiasis, 49, 27-39. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Wang, W., Fan, J., Huang, G., et al. (2017) Prevalence of Kidney Stones in Mainland China: A Systematic Review. Scientific Reports, 7, Article No. 41630. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ye, Z., Zeng, G., Yang, H., et al. (2020) The Status and Characteristics of Urinary Stone Composition in China. BJU International, 125, 801-809. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wang, Z., Zhang, Y., Zhang, J., et al. (2021) Recent Advances on the Mechanisms of Kidney Stone Formation (Review). International Journal of Molecular Medicine, 48, Article 149. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Stamatelou, K. and Goldfarb, D.S. (2023) Epidemiology of Kidney Stones. Healthcare, 11, Article 424. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Wagner, C.A. (2021) Etiopathogenic Factors of Urolithiasis. Archivos Españoles de Urología, 74, 16-23.
|
|
[8]
|
Felber, J.G., Kitowski, A., Zeisel, L., et al. (2023) Cyclic Dichalcogenides Extend the Reach of Bioreductive Prodrugs to Harness Thiol/Disulfide Oxidoreductases: Appli-cations to Seco-Duocarmycins Targeting the Thioredoxin System. ACS Central Science, 9, 763-76. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Jastrząb, A. and Skrzydlewska, E. (2020) Thioredox-in-Dependent System. Application of Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 36, 362-371. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Hawkes, H.J.K., Karlenius, T.C. and Tonis-sen, K.F. (2014) Regulation of the Human Thioredoxin Gene Promoter and Its Key Substrates: A Study of Func-tional and Putative Regulatory Elements. Biochimica et Biophysica Acta (BBA)— General Subjects, 1840, 303-314. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Patwardhan, R.S., Sharma, D. and Sandur, S.K. (2022) Thioredoxin Reductase: An Emerging Pharmacologic Target for Radiosensitization of Cancer. Translational On-cology, 17, Article ID: 101341. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Medali, T., Couchie, D., Mougenot, N., et al. (2023) Thi-oredoxin-1 and Its Mimetic Peptide Improve Systolic Cardiac Function and Remodeling after Myocardial Infarction. The FASEB Journal, 38, e23291. [Google Scholar] [CrossRef]
|
|
[13]
|
Hasan, A.A., Kalinina, E., Tatarskiy, V. and Shtil, A. (2022) The Thioredoxin System of Mammalian Cells and Its Modulators. Biomedicines, 10, Article 1757. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Pan, M., Zhang, F., Qu, K., et al. (2022) TXNIP: A Double-Edged Sword in Disease and Therapeutic Outlook. Oxidative Medicine and Cellular Longevity, 2022, Ar-ticle ID: 7805115. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kansal, H., Chopra, V., Garg, K. and Sharma, S. (2023) Role of Thioredoxin in Chronic Obstructive Pulmonary Disease (COPD): A Promising Future Target. Res-piratory Research, 24, Article No. 295. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Pan, Y., Lu, Y., Zhou, J.D., et al. (2022) Prospect of Thi-oredoxin as a Possibly Effective Tool to Combat OSAHS. Sleep and Breathing, 27, 421-429. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Liu, Y., Xue, N., Zhang, B., et al. (2022) Role of Thiore-doxin-1 and Its Inducers in Human Health and Diseases. European Journal of Pharmacology, 919, Article ID: 174756. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Zhu, M., Dagah, O.M.A., Silaa, B.B., et al. (2023) Thioredoxin/Glutaredoxin Systems and Gut Microbiota in NAFLD: Interplay, Mechanism, and Therapeutical Po-tential. Antioxidants, 12, Article 1680. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Halliwell, B. (2023) Understanding Mechanisms of Antioxidant Action in Health and Disease. Nature Reviews Molecular Cell Biology, 25, 13-33. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Ulasov, A.V., Rosenkranz, A.A., Georgiev, G.P., et al. (2022) Nrf2/Keap1/ARE Signaling: Towards Specific Regulation. Life Sciences, 291, Article ID: 120111. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Ghareeb, H. and Metanis, N. (2020) The Thioredoxin System: A Promising Target For Cancer Drug Development. Chemistry: A European Journal, 26, 10175-10184. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Tian, Z.K., Zhang, Y.J., Feng, Z.J., et al. (2021) Nephropro-tective Effect of Gastrodin against Lead-Induced Oxidative Stress and Inflammation in Mice by the GSH, Trx, Nrf2 Antioxidant System, and the HMGB1 Pathway. Toxicology Research, 10, 249-263. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wigner, P., Grębowski, R., Bijak, M., et al. (2021) The Molecular Aspect of Nephrolithiasis Development. Cells, 10, Article 1926. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Donate-Correa, J., Martín-Carro, B., Cannata-Andía, J.B., et al. (2023) Klotho, Oxidative Stress, and Mitochondrial Damage in Kidney Disease. Antioxidants, 12, Article 239. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Mendez-Barbero, N., Oller, J., Sanz, A.B., et al. (2023) Mito-chondrial Dysfunction in the Cardio-Renal Axis. International Journal of Molecular Sciences, 24, Article 8209. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Evan, A.P., Worcester, E.M., Coe, F.L., et al. (2015) Mechanisms of Human Kidney Stone Formation. Urolithiasis, 43, 19-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Saenz-Medina, J., Muñoz, M., Rodriguez, C., et al. (2022) Endothelial Dysfunction: An Intermediate Clinical Feature between Urolithiasis and Cardiovascular Diseases. In-ternational Journal of Molecular Sciences, 23, Article 912. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Alokda, A. and Van Raamsdonk, J.M. (2023) Evolutionarily Conserved Role of Thioredoxin Systems in Determining Longevity. Antioxidants, 12, Article 944. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Zhang, Q., Liu, J., Duan, H., et al. (2021) Activation of Nrf2/HO-1 Signaling: An Important Molecular Mechanism of Herbal Medicine in the Treatment of Atherosclerosis via the Protection of Vascular Endothelial Cells from Oxidative Stress. Journal of Advanced Research, 34, 43-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Jakobs, P., Serbulea, V., Leitinger, N., et al. (2017) Nuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart. Antioxidants & Redox Signaling, 26, 630-644. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Lukosz, M., Jakob, S., Büchner, N., et al. (2010) Nuclear Redox Signaling. Antioxidants & Redox Signaling, 12, 713-742. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Oberacker, T., Kraft, L., Schanz, M. and Latus, J. (2023) The Importance of Thioredoxin-1 in Health and Disease. Antioxidants, 12, Article 1078. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Wang, J., Bai, Y., Yin, S., et al. (2021) Circadian Clock Gene BMAL1 Reduces Urinary Calcium Oxalate Stones Formation by Regulating NRF2/HO-1 Pathway. Life Sciences, 265, Article ID: 118853. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Ahmatjan, B., Ruotian, L., Rahman, A., et al. (2023) Klotho Inhibits the Formation of Calcium Oxalate Stones by Regulating the Keap1-Nrf2-ARE Signaling Pathway. Inter-national Urology and Nephrology, 55, 263-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Zhang, X., Liang, F., Li, T., et al. (2023) Metformin Ame-liorates Calcium Oxalate Crystallization and Stone Formation by Activating the Nrf2/HO-1 Signaling Pathway: Two Birds with One Stone. Archives of Biochemistry and Biophysics, 739, Article ID: 109568. [Google Scholar] [CrossRef] [PubMed]
|